Ideas

February 18, 2019

Published by admin_auro at February 18, 2019

Categories

Cancer
Ideas

Combinatorial therapy for glioblastoma: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) [SAN] inhibits the expression of JMJD6, impairs functioning of transcription elongation machinery, inhibits the proliferation of glioblastoma cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down-regulation of its target gene, 18/February/2019, 1.07 pm

Introduction: What they say: A study from the Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Ohio, USA shows that “Transcription elongation factors […]

February 18, 2019

Published by admin_auro at February 18, 2019

Categories

Molecular therapy for Diabetes Mellitus: Canagliflozin(trade name Invokana or Sulisent), a sodium-glucose cotransporter-2 inhibitor used in the treatment of TIIDM, augments the expression of FGF19 and FGF1, attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 18/February/2019, 1.00 pm

Introduction: What they say A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection […]

February 18, 2019

Published by admin_auro at February 18, 2019

Categories

Cancer
Ideas

Combinatorial therapy for drug-resistant cancers: A therapeutic mix encompassing Simvastatin and Navitoclax (ABT-263) (SAN) inhibits the expression of phospholipid glutathione peroxidase (GPX4), inhibits GPX4 signaling network and lipid peroxidase pathway, suppresses EMT protein ZEB1, increases sensitivity to anticancer therapy and prolongs survival via upregulation of its target gene, 18/February/2019, 12.49 pm

Introduction: What they say: A study from Broad Institute, Cambridge, Massachusetts, USA, Howard Hughes Medical Institute, Chevy Chase, Maryland and Department of Chemistry and Chemical Biology, […]

February 18, 2019

Published by admin_auro at February 18, 2019

Categories

Cholic acid-based therapy for Autoimmune diabetes: Tauroursodeoxycholic Acid (TUDCA) increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up-regulation of its target gene, 30/January/2019, 9.27 am

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical […]